SYRE Spyre Therapeutics, Inc.

Spyre Therapeutics (NasdaqGS:SYRE) reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003. The Phase 2 study delivered clinical proof-of-concept for SPY003, the firm's anti-IL-23 therapy for ulcerative colitis. Management also reported biological proof-of-concept for all three immunology mechanisms in Spyre Therapeutics' inflammatory bowel disease portfolio. The positive 12-week SKYLINE Part A results for SPY003 and Spyre's IBD mechanisms deserve to be...

On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart’s Histopathology Index score at Week 12 with a p-value below 0.0001. That result matters because it closes out a run of three straight readouts. […]

Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ulcerative colitis in the open-label Part A of the Phase 2 SKYLINE trial. At week 12, the mean Robarts Histopathology Index, a measure of tissue inflammation, declined by 10 points. Clinical remission, measured by the modified Mayo Score, was […]

SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) fell 13% to $94 on August 26, 2026, but the sell-off sharply overreacted to the underlying data. The company’s SPY072 asset, tested in a rheumatoid arthritis sub-study of the Phase 2 SKYWAY trial reported August 25, cleared statistical significance versus placebo on one or more of the primary DAS28-CRP endpoints and […]

Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.

Investing.com - U.S. stock futures hovered around the flatline on Wednesday, as investors remained cautious ahead of the latest U.S. inflation data and Nvidia’s quarterly results, with both events likely to offer fresh clues on the outlook for interest rates and the durability of the artificial intelligence trade.

Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum. Shares are trading at a new 3-year high. SYRE maintains a 100% “Buy” technical opinion from Barchart. Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk...

Spyre Therapeutics has delivered a very strong 3 year return while its current valuation checks suggest the stock is not cheap, which raises questions about how much of the recent optimism is already in the price. The stock has returned roughly 7x over the past 3 years, which is an unusually large move that can leave new buyers with less room for error if expectations cool. Positive Phase 2 data across key ulcerative colitis programs can support higher growth expectations, but the reliance...

This disposition follows a staggering 500% one-year stock surge.

This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 months.

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.